drugset / Trial / NCT01466764
Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain
RandomizedParallel-groupTriple-blindTreatment
Summary
The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.
Timeline
- Start
- 2011-10
- Primary completion
- 2013-05
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |
Indications
No indication recorded.